Company & Sponsor Intelligence
University of Oxford
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials6
Recruiting0
Completed4
Countries2
Therapeutic footprint
alzheimersautismdepressionepilepsyunclassified
Indexed studies
NCT04257331Parent Training to Reduce Behavioral Problems in Children With Autism Spectrum Disorder in China
autism · ChinaNA
autism · ChinaNA
NCT04080674Using DBS to Probe Basal Ganglia Dysfunction
parkinsons · United KingdomUNKNOWN
parkinsons · United KingdomUNKNOWN
NCT03489044An Investigation of Levetiracetam in Alzheimer's Disease
epilepsy · United KingdomPHASE2
epilepsy · United KingdomPHASE2
NCT04141904Tofacitinib in Depression (TIDE)
depression · United KingdomPHASE1,PHASE2
depression · United KingdomPHASE1,PHASE2
NCT05850975Do Mind Ease Interventions Reduce Feelings of Acute Anxiety? A Randomised Controlled Trial
alzheimers · United KingdomNA
alzheimers · United KingdomNA
NCT00461318The Effectiveness of Supported Employment for People With Severe Mental Illness: an RCT in Six European Countries
unclassified · United KingdomNA
unclassified · United KingdomNA
NCT01085383Aripiprazole and Prolactin Study
unclassified · United KingdomPHASE4
unclassified · United KingdomPHASE4
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →